Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma

Kevin C. Hart, Daniel Santos, Keyu Li, Rui Yun, Min Chai, Andras Kabai, Gene Li, Poonam Yakkundi, Roel P. Funke, Yinghui Guan, Thomas Manley, Liqin Liu, Angus M. Sinclair, Albert F. Candia, Bruce Keyt, Maya F. Kotturi

Cancer Res (2024) 84 (6_Supplement): 1237.

https://doi.org/10.1158/1538-7445.AM2024-1237

Published: 22 March 2024

View articletitled, Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma

Journal Articles

Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

Andrew X. Zhu, Yinghui Guan, Alexander R. Abbas, Hartmut Koeppen, Shan Lu, Chih-Hung Hsu, Kyung-Hun Lee, Michael S. Lee, Aiwu Ruth He, Amit Mahipal, Beiying Ding, Jessica Spahn, Wendy Verret, Baek-Yeol Ryoo, Yulei Wang

Cancer Res (2020) 80 (16_Supplement): CT044.

https://doi.org/10.1158/1538-7445.AM2020-CT044

Published: 15 August 2020

View articletitled, Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

Journal Articles

Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Cancer Res (2019) 79 (13_Supplement): 463.

https://doi.org/10.1158/1538-7445.AM2019-463

Published: 01 July 2019

View articletitled, Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Journal Articles

Abstract 2740: High-throughput and sensitive quantification of circulating tumor DNA

Yinghui Guan, Oleg Mayba, Shan Lu, Thomas Sandmann, Younjeong Choi, Walter Darbonne, Vincent Leveque, Lisa Ryner, Eric Humke, Nga W. Tam, Sundari Sujathasarma, Anna Cheung, Richard Bourgon, Yulei Wang

Cancer Res (2017) 77 (13_Supplement): 2740.

https://doi.org/10.1158/1538-7445.AM2017-2740

Published: 01 July 2017

View articletitled, Abstract 2740: High-throughput and sensitive quantification of circulating tumor DNA

Journal Articles

Abstract 3395: BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.

Marie Wagle, Matthew Wongchenko, Shan Lu, Yinghui Guan, Yulei Wang, Mark Lackner, Garret Hampton, Yibing Yan

Cancer Res (2013) 73 (8_Supplement): 3395.

https://doi.org/10.1158/1538-7445.AM2013-3395

Published: 15 April 2013

View articletitled, Abstract 3395: BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.

Journal Articles

Abstract 3479: Sensitivity of endometrial cancer cells to inhibitors targeting different nodes of the PI3K pathway and their combination with a MEK inhibitor.

Matthew J. Wongchenko, Yinghui Guan, Marie-Claire Wagle, Lisa Ryner, Shan Lu, Hartmut Koeppen, Garret Hampton, Mark Lackner, Yulei Wang, Yibing Yan

Cancer Res (2013) 73 (8_Supplement): 3479.

https://doi.org/10.1158/1538-7445.AM2013-3479

Published: 15 April 2013

View articletitled, Abstract 3479: Sensitivity of endometrial cancer cells to inhibitors targeting different nodes of the PI3K pathway and their combination with a MEK inhibitor.

Journal Articles

Abstract 3231: Comprehensive profiling of actionab.

Yulei Wang, Richard Bourgon, Shan Lu, Yibing Yan, Yinghui Guan, Lisa Ryner, Rajesh Partel, Mark Lackner, Lukas Amler

Cancer Res (2013) 73 (8_Supplement): 3231.

https://doi.org/10.1158/1538-7445.AM2013-3231

Published: 15 April 2013

View articletitled, Abstract 3231: Comprehensive profiling of actionab.

Journal Articles

Abstract 3213: A rapid, sensitive and quantitative method to measure protein biomarkers MUC16 and MSLN from archived clinical samples using TaqMan proximity ligation assays.

Lisa Ryner, Aimee Fourie, Siao Ping Tsai, Suzie Scales, Kathy Kozak, Ron Firestein, Yinghui Guan, An Do, Yulei Wang

Cancer Res (2013) 73 (8_Supplement): 3213.

https://doi.org/10.1158/1538-7445.AM2013-3213

Published: 15 April 2013

View articletitled, Abstract 3213: A rapid, sensitive and quantitative method to measure protein biomarkers MUC16 and MSLN from archived clinical samples using TaqMan proximity ligation assays.

Journal Articles

Abstract 1941: Identification of microRNA(miRNA) signature genes for chemoresistance through high throughput profiling of cancer related miRNAs (OncomiRs) in ovarian cancer cell lines and formalin fixed, paraffin embedded (FFPE) ovarian tissues.

Yinghui Guan, Shan Lu, Lisa Ryner, Yulei Wang

Cancer Res (2013) 73 (8_Supplement): 1941.

https://doi.org/10.1158/1538-7445.AM2013-1941

Published: 15 April 2013

View articletitled, Abstract 1941: Identification of microRNA(miRNA) signature genes for chemoresistance through high throughput profiling of cancer related miRNAs (OncomiRs) in ovarian cancer cell lines and formalin fixed, paraffin embedded (FFPE) ovarian tissues.

Journal Articles

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

Cancer Res (2009) 69 (2): 565–572.

https://doi.org/10.1158/0008-5472.CAN-08-3389

Published: 15 January 2009

View articletitled, Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

Includes: Supplementary data

Journal Articles

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

Cancer Res (2008) 68 (15): 6084–6091.

https://doi.org/10.1158/0008-5472.CAN-07-6854

Published: 01 August 2008

View articletitled, An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

Includes: Supplementary data

Journal Articles

p27kip1 inhibition can rescue the cell cycle block induced by myc knockdown in MYC-amplified ovarian cancer cells

Tulsiram Prathapam, Alexey Aleshin, Yinghui Guan, Joe Gray, G. Steven Martin

Cancer Res (2008) 68 (9_Supplement): 93.

Published: 01 May 2008

View articletitled, p27kip1 inhibition can rescue the cell cycle block induced by myc knockdown in MYC-amplified ovarian cancer cells

Journal Articles

Identification of new therapeutic targets of breast cancer using siRNA technology

Zhi Hu, Richard Neve, Yinghui Guan, Joe Gray

Cancer Res (2007) 67 (9_Supplement): 4956.

Published: 01 May 2007

View articletitled, Identification of new therapeutic targets of breast cancer using siRNA technology

Journal Articles

Molecular predictors of drug response in breast cancer

Wen-Lin Kuo, Yinghui Guan, Zhi Hu, Debopriya Das, Nick Wang, Heidi Feiler, Richard Neve, Joe Gray

Cancer Res (2007) 67 (9_Supplement): 4963.

Published: 01 May 2007

View articletitled, Molecular predictors of drug response in breast cancer

Journal Articles

An adaptive approach to predicting chemosensitivity of tissue-specific cancer cells

Debopriya Das, Wen-Lin Kuo, Yinghui Guan, Zhi Hu, Nick Wang, Nora Bayani, Heidi Feiler, Paul Spellman, Richard Neve, Joe Gray

Cancer Res (2007) 67 (9_Supplement): LB-254.

Published: 01 May 2007

View articletitled, An adaptive approach to predicting chemosensitivity of tissue-specific cancer cells

Journal Articles

Functional assessment of genes in the 8q24 amplicon in ovarian cancer

Yinghui Guan, Wen-Lin Kuo, Hirokuni Takano, Robert Vincent, David Konczal, Anna Lapuk, Joe Gray

Cancer Res (2005) 65 (9_Supplement): 846–847.

Published: 01 May 2005

View articletitled, Functional assessment of genes in the 8q24 amplicon in ovarian cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma

Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Abstract 2740: High-throughput and sensitive quantification of circulating tumor DNA

Abstract 3395: BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.

Abstract 3479: Sensitivity of endometrial cancer cells to inhibitors targeting different nodes of the PI3K pathway and their combination with a MEK inhibitor.

Abstract 3231: Comprehensive profiling of actionab.

Abstract 3213: A rapid, sensitive and quantitative method to measure protein biomarkers MUC16 and MSLN from archived clinical samples using TaqMan proximity ligation assays.

Abstract 1941: Identification of microRNA(miRNA) signature genes for chemoresistance through high throughput profiling of cancer related miRNAs (OncomiRs) in ovarian cancer cell lines and formalin fixed, paraffin embedded (FFPE) ovarian tissues.

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

p27kip1 inhibition can rescue the cell cycle block induced by myc knockdown in MYC-amplified ovarian cancer cells

Identification of new therapeutic targets of breast cancer using siRNA technology

Molecular predictors of drug response in breast cancer

An adaptive approach to predicting chemosensitivity of tissue-specific cancer cells

Functional assessment of genes in the 8q24 amplicon in ovarian cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only